Wegovy vs Zepbound for Women Over 50: What You Need to Know

If you're a woman over 50 considering weight loss medication, you've likely heard about Wegovy and Zepbound. These two medications represent the most effective pharmaceutical options available today, but they work differently in your body. Understanding these differences matters even more after 50, when hormonal changes, metabolism shifts, and health priorities evolve.

Let's break down what makes each medication unique and what the research tells us about using them during this stage of life.

Understanding the Basics: What Are Wegovy and Zepbound?

Both Wegovy and Zepbound are injectable medications approved by the FDA for chronic weight management. They belong to a class of drugs called GLP-1 receptor agonists, which work by mimicking hormones that regulate appetite and blood sugar.

Wegovy contains semaglutide, a single-hormone medication that activates GLP-1 receptors. It's been on the market longer and has extensive research backing its use for weight loss.

Zepbound contains tirzepatide, a dual-action medication that activates both GLP-1 and GIP receptors. This newer approach may offer additional metabolic benefits beyond appetite control.

Both are once-weekly injections administered at home with a pre-filled pen.

How They Work Differently in Your Body

The key distinction lies in how each medication interacts with your metabolism.

Wegovy focuses exclusively on the GLP-1 pathway, which slows stomach emptying, reduces appetite, and helps regulate blood sugar. Clinical trials show an average weight loss of 15-17% of body weight over 68 weeks.

Zepbound adds GIP receptor activation to the mix. GIP affects how your body stores fat and may improve insulin sensitivity differently than GLP-1 alone. Studies demonstrate an average weight loss of 18-21% of body weight over 72 weeks.

For women over 50, these mechanisms matter because menopause often brings increased visceral fat storage and insulin resistance. The dual-action approach of Zepbound may address these specific metabolic changes more directly.

What the Research Shows for Older Adults

Clinical trials for both medications included participants over 50, though specific analyses for this age group are limited.

What we do know: older adults generally respond well to both medications, though individual results vary significantly. Some women over 50 report slightly slower weight loss compared to younger participants, but the total weight reduction remains substantial.

Neither medication appears to work dramatically better or worse based on age alone. Your individual health profile matters more than your birthday.

Considerations Specific to Women Over 50

Several factors become more relevant when choosing between these medications after 50.

Menopause and Metabolic Changes

Post-menopausal women often experience changes in fat distribution, with more weight settling around the midsection. Both medications can help address this stubborn abdominal fat, though Zepbound's dual mechanism may offer a slight edge for metabolic improvements.

Hot flashes, sleep disruption, and mood changes during perimenopause and menopause can affect eating patterns. Some women find that GLP-1 medications help stabilize their appetite despite these hormonal fluctuations.

Bone Health Considerations

Rapid weight loss at any age can impact bone density, a particular concern for women over 50 who already face increased osteoporosis risk. This isn't specific to either medication, but it's an important conversation to have with your physician.

Ensuring adequate protein intake, calcium, vitamin D, and weight-bearing exercise becomes even more critical when using these medications.

Existing Health Conditions

Women over 50 are more likely to have conditions like high blood pressure, high cholesterol, or type 2 diabetes. Both Wegovy and Zepbound improve these metabolic markers, with some studies suggesting tirzepatide (Zepbound) may have stronger effects on blood sugar control.

If you're already taking multiple medications, drug interactions and management complexity become important factors in your decision.

Side Effects: What to Expect

Both medications share common side effects, primarily gastrointestinal.

Nausea, constipation, diarrhea, and occasional vomiting occur most frequently during dose increases. These effects typically diminish over time as your body adjusts.

Some women over 50 report being more sensitive to these side effects, though this isn't universal. Starting slowly and titrating carefully can minimize discomfort.

Zepbound may cause slightly higher rates of nausea in the first few weeks, but many users find these effects manageable with proper hydration and eating adjustments.

Cost and Accessibility

Both brand-name medications carry similar high price tags, often $1,000-$1,300 per month without insurance coverage.

Insurance coverage varies significantly. Some plans cover one but not the other, or require step therapy where you must try one before accessing the other.

Compounded versions of semaglutide and tirzepatide offer more affordable alternatives at significantly lower costs, making these treatments accessible to more women who could benefit from them.

Making Your Decision

No single medication is universally better for all women over 50.

Consider Wegovy if you prefer a medication with longer-term safety data, or if you've had success with semaglutide in the past. Its track record is extensive, and many physicians have more experience prescribing it.

Consider Zepbound if maximizing weight loss is your primary goal and you're comfortable with a newer medication. The dual mechanism may offer additional metabolic benefits, particularly for blood sugar management.

Most importantly, this decision should be made with a physician who understands your complete health picture, including your medical history, current medications, and personal health goals.

From the Ozari Care Team

We find that women over 50 often do best when they start at lower doses and increase more gradually than younger patients. This approach minimizes side effects while still achieving excellent results. Remember that sustainable weight loss is a marathon, not a sprint—patience with the process leads to better long-term outcomes.

Get Started with Affordable GLP-1 Therapy

At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically reviewed by the Ozari Clinical Care Team, licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 26, 2026